Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > DrDR is AWESOME!!!! EOM
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(331)
•••
Comment by regardlesson Jan 11, 2021 1:01pm
251 Views
Post# 32267810

RE:RE:RE:RE:RE:DrDR is AWESOME!!!! EOM

RE:RE:RE:RE:RE:DrDR is AWESOME!!!! EOM

The way I look at it as barsax talked about...
they need to try and exercise those April warrants.

an injection of 5 million into our coffers would be huge! 

we need 1$ a share for I belive a week ... but just having that exercised may very well run this up to 1.2-1.4$ 
the question now is , what can bioasis do between now and then to get this up to 1$
A decent deal may get us there ... two deals may send this even higher then they exercise at a great rate of the price were to run up to 2$ 

look you never know but we have so much more today then we did in 2015 on that run to 2.10$ that you have to give it seriouse considerations in regards to it getting back there in q1 

I always get super confident then get deflated like a Swedish penes pump .... but man if this is intact theeee quarter that many have promoted them I belive it can get there 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities